Adoptive immunotherapy with donor lymphocyte transfusions

Current Opinion in Oncology

Volumn 9, Issue 2, 1997, Pages 139-145

  Kolb, Hans Jochem ^a   Holler, Ernst ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD8 ANTIGEN; INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; CELL TRANSPLANTATION; CHIMERA; CHRONIC MYELOID LEUKEMIA; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOCOMPETENT CELL; LEUKEMIA; LYMPHOCYTE; LYMPHOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0030986821     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199703000-00006     Document Type: Review

References (53)

1. Barnes DHW, Loutit JF: Treatment of murine leukaemia with X-rays and homologous bone marrow. Br J Haematol 1957, 3:241-252.
2. Mathé G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M: Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res 1965, 25:1525-1530.
3. Mathé G, Amiel JL, Schwartzenberg L, Cattan A, Schneider M, De Vries JM, Tubiana M, Lalanne C, Binet JL, Papiernik M, et al.: Successful allogeneic bone marrow transplantation in man: chimerism, induced specific tolerance and possible antileukemic effects. Blood 1965, 25:179.
4. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, for the Seattle Marrow Transplant Team: Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981, 304:1529-1531.
5. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, et al.: Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989, 73:1720-1728.
6. Rodt H, Kolb HJ, Netzel B, Hoffman-Fezer G, Thierfelder S: Serological Prevention of graft-versus-host disease: an experimental and clinical survey. In Tolerance in Bone Marrow and Organ Transplantation. Edited by Slavin S. Elsevier Science Publishers: Amsterdam; 1984:253-285.
7. Apperley JF, Mauro FR, Goldman JM, et al.: Bone marrow transplantation for chronic myeloid leukemia in first chronic phase: importance of a graft-versus-leukemia effect. Br J Haematol 1988, 69:239-245.
8. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB, et al.: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988, 108:806.
9. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
10. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Babaji M, Hansen J, et al.: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989, 320:828-834.
11. Naparstek E, Or R, Nagler A, Cividalli G, Engelhard D, Aker M, Gimon Z, Manny N, Sacks T, Tochner Z, et al.: T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using campath-1 antibodies and post-transplant administration of donors peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995, 89:506-515.
12. Slavin S, Ackerstein A, Weiss L, Nagler A, Or R, Naparstek E: Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 1992, 10:221-227.
13. Tutschka P, Schwerdtfeger R, Slavin R, Santos GW: Mechanism of donor to host tolerance in rat bone marrow chimeras. In Experimental Hematology Today, 1st edn. Edited by Siegmund J, Baum G, David L. New York: Springer; 1977:191-197.
14. Weiden PL, Storb R, Tsoi M-S, Graham TC, Lerner KG, Thomas ED: Infusion of donor lymphocytes into stable canine radiation chimeras: implications for mechanism of transplantation tolerance. J Immunol 1976, 116:1212-1219.
15. Johnson BD, Drobyski WR, Truitt RL: Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 1993, 11:329-336.
16. Kolb HJ, Beisser K, Holler E, Mittermuller J, Clemm C, Walther U, Schumm M, Ledderose G, Wilmanns W, Thierfelder S: Donor buffy coat transfusions for adoptive immunotherapy in human and canine chimeras. Periodicum Biologorum 1991, 93:81-96.
17. Kolb HJ, Mittermueller J, Clemm C, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
18. Flowers M, Sullivan KM, Martin P, et al.: Use of peripheral blood stem cells for immune therapy [abstract]. Blood 1995, 86:564.
19. Goulmy E, Termijteelen A, Bradley BA, Van Rood JJ: Y-antigen killing by T-cells of women is restricted by HLA. Nature 1977, 266:544-545.
20. Lönnqvist B, Brune M, Ljungman P: Lymphoblastoid human interferon and low dose IL-2 combined with donor lymphocyte infusion as therapy of a third relapse of CML: a case report. Bone Marrow Transplant 1996, 18:241-242.
21. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L. Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, Small TM, Young JW, O'Reilly RJ: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995, 86:1261-1268. Dose-finding study of donor T cells in CML patients.
22. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, Körbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R: CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995, 86:4337-4343. Demonstration that graft-versus-leukemia effect is exerted by CD8 depleted T cells.
23. Bonini C, Verzelletti S, Servida P, Rossini S, Traversari C, Ferrari G, Nobili N, Mavilio F, Bordignon C: Transfer of HSV-TK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor antitumor immunity after allo-BMT [abstract]. Blood 1994, 84:110.
24. Jiang YZ, Cullis JO, Kanfer EJ, Goldman JM, Barrett AJ: T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 1993, 11:133-138.
25. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050. Largest study on donor lymphocyte transfusions.
26. Porter DL, Roth MS, Lee SJ, McGarigle C, Ferrara JLM, Antin JH: Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996, 18:975-980.
27. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996, 87:2195-2204.
28. Ferster A, Bujan W, Mouraux T, Devalck C, Heimann P, Sariban E: Complete remission following donor leukocyte infusion in ALL relapsing after haploidentical bone marrow transplantation. Bone Marrow Transplant 1994, 14:331-332.
29. Russell LA, Jacobsen N, Heilmann C, Simonsen AC, Christensen LD, Vindelov LL: Treatment of relapse after allogeneic BMT with donor leukocyte infusions in 16 patients. Bone Marrow Transplant 1996, 18:411-414.
30. SMit WM, Rijnbeck M, Van Bergen CAM, De Paus RA, Willemze R, Falkenburg JHF: Dendritic cells generated from FACS sorted chronic myeloid leukemia (CML) precursor cells express BCR/ABL, and are potent stimulators for allogeneic T cells [abstract]. Br J Haematol 1996, 93:313.
31. Mittermüller J, Kolb HJ, Gerhartz HH, Wilmanns W: In vivo differentiation of leukemic blasts and effect of low dose ara-c in a marrow grafted patient with leukemic relapse. Br J Haematol 1986, 62:757-762.
32. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B: Graft-versus-myeloma effect: proof of principle. Blood 1996, 87:1196-1198. Demonstration of a graft-versus-myeloma effect.
33. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EF: Graft-versus-myeloma effect in two cases. Lancet 1996, 347:800-801.
34. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gächter A, Knapp R, Böck G, Gassner C, Schiller L, Petersen FB, Niederwieser D: Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996, 88:1501-1508.
35. Boasberg PD, Tokita KM, Terasaki PI, Wang X: Lymphocyte transfusion therapy for cancer patients. Blood 1996, 87:3522-3523.
36. Schattenberg A, van de Wiel-van Kemenade E, Schaap N, De Witte T: Chimerism and outcome of the infusion of lymphocytes as a treatment for relapse after T cell depleted BMT [abstract]. Bone Marrow Transplant 1996, 17(Suppl 1):S9.
37. Chen W, Peace BJ, Rovira DK, You SG, Cheever MA: T-cell immunity to the joining region of p210 BCR-ABL protein. Proc Natl Acad Sci U S A 1992, 89:1468-1471.
38. Ten Bosch GJA, Joosten AM, Kessler JH, Melief CJM, Leeksma OC: Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL break-point peptide. Blood 1996, 88:3522-3527.
39. Mannering SI, McKenzie JL, Hart DN: Generation of T-lymphocyte clones specific for the BCR-ABL fusion peptide presented by dendritic cells and other antigen presenting cells [abstract]. Bone Marrow Transplant 1996, 17(Suppl 1).S59. Induction of cytotoxic T cells to dendritic cells carrying bcr-abl fusion peptide.
40. Bunjes D, Hertenstein B, Wiesneth M, Novotny J, Frickhofen N, Arnold R, Heimpel H: Donor lymphocyte transfusions and low-dose interleukin-2 in 2 patients with relapsed CML after syngeneic BMT [abstract]. Bone Marrow Transplant 1996. 17(Suppl 1):S9.
41. Goulmy E: Minor H antigens: a "1993" look into their perspectives. Bone Marrow Transplant 1993, 12(Suppl 4):9-10.
42. Kolb HJ, Mittermüller J, Holler E, Thalmeier K, Bartram CR: Graft-versus-host reaction spares normal stem cells in chronic myelogenous leukemia. Bone Marrow Transplant 1996, 17:449-452.
43. Verfaillie CM, Miller WJ, Boylan K, McGlave PB: Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of MLA-DR antigen expression. Blood 1992, 79:1003-1010.
44. Duncombe AS, Heslop HE, Turner M, Meager A, Priest R, Exley T, Brenner MK: Tumor necrosis factor mediates autocrine growth inhibition in a chronic leukemia. J Immunol 1989, 143:3828-3834.
45. Ruiz Cabello F, Klein E, Garrido F: MHC antigens on human tumors. Immunol Lett 1991, 29:181-189.
46. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1993, 327:1209-1215.
47. Kwak LW, Taub DD, Duffey PL. Bensinger WI, Bryant EM, Reynolds CW, Longo DL: Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor [abstract]. Lancet 1995, 345:1016-1020. Successful transfer of T-cell immunity by myeloma protein.
48. Nelson EL, Li X, Hsu FJ, Kwak LW, Levy R, Clayberger C, Krensky AM: Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkins lymphoma [abstract]. Blood 1996, 88:580-589. Vaccination resulting in cytotoxic T-cell immunity to antibody idiotype.
49. Tiberghien P, Reynolds CW, Keller J, Spence S, Deschaseaux M, Certou JM, Contassot E, Murphy WJ, Lyons R, Chiang Y, et al.: Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo T-cells depletion after bone marrow transplantation. Blood 1994, 84:1333-1341.
50. Papadopouplos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, et al.: Infusions of donor leukocytes to treat Epstein-Bar virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994, 330:1185-1191.
51. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE: Early identification of Epstein-Barr virus-associated post transplantation lymphoproliferative disease. Br J Haematol 1995, 89:98-103.
52. Heslop HE, Brenner MK, Rooney CM: Donor T cells as therapy for EBV lymphoproliferation post bone marrow transplantation. N Engl J Med 1994, 331:679-680.
53. Rooney CM, Smith CA, Ng CYC, Loftin SK, Li CL, Krance RA, Brenner MK, Heslop HE: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995, 345:9-13. This report shows the survival of gene-modified donor T cells in marrow transplantation patients.